Regen BioPharma Inc. announced the appointment of Dr. Amit Patel to the company's Scientific Advisory Board (SAB). Dr. Patel is Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and has been involved in over 17 FDA trials in the area of cellular therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -.--% | -4.76% | +5.26% |
1st Jan change | Capi. | |
---|---|---|
+5.26% | 4.17M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- RGBP Stock
- News Regen BioPharma, Inc.
- Regen Biopharma Inc. Appoints Amit Patel to its Scientific Advisory Board